• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于日本全国性调查的扩大活体供肝肝移植标准用于肝细胞癌患者:5-5-500 规则-一项回顾性研究。

Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study.

机构信息

Division of Organ Transplantation, Hokkaido University Hospital, Sapporo, Japan.

Artificial Organ and Transplantation Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

出版信息

Transpl Int. 2019 Apr;32(4):356-368. doi: 10.1111/tri.13391. Epub 2019 Jan 18.

DOI:10.1111/tri.13391
PMID:30556935
Abstract

Expansion of the liver transplantation indication criteria for patients with hepatocellular carcinoma (HCC) has long been debated. Here we propose new, expanded living-donor liver transplantation (LDLT) criteria for HCC patients based on a retrospective data analysis of the Japanese nationwide survey. A total of 965 HCC patients undergoing LDLT were included, 301 (31%) of whom were beyond the Milan criteria. Here, we applied the Greenwood formula to investigate new criteria enabling the maximal enrollment of candidates while securing a 5-year recurrence rate (95% upper confidence limit) below 10% by examining various combinations of tumor numbers and serum alpha-fetoprotein values, and maintaining the maximal nodule diameter at 5 cm. Finally, new expanded criteria for LDLT candidates with HCC, the 5-5-500 rule (nodule size ≤5 cm in diameter, nodule number ≤5, and alfa-fetoprotein value ≤500 ng/ml), were established as a new regulation with a 95% confidence interval of a 5-year recurrence rate of 7.3% (5.2-9.3) and a 19% increase in the number of eligible patients. In addition, the 5-5-500 rule could identify patients at high risk of recurrence, among those within and beyond the Milan criteria. In conclusion, the new criteria - the 5-5-500 rule - might provide rational expansion for LDLT candidates with HCC.

摘要

扩大肝细胞癌(HCC)患者的肝移植适应证标准一直存在争议。在这里,我们根据日本全国性调查的回顾性数据分析,提出了新的扩展的活体供肝肝移植(LDLT)HCC 患者标准。共纳入 965 例接受 LDLT 的 HCC 患者,其中 301 例(31%)超出米兰标准。在这里,我们应用 Greenwood 公式研究了新的标准,通过检查肿瘤数量和血清甲胎蛋白值的各种组合,同时保持最大结节直径为 5cm,以确保 5 年复发率(95%置信上限)低于 10%,从而最大程度地招募候选者。最后,建立了新的 LDLT 候选 HCC 的扩展标准,即 5-5-500 规则(结节直径≤5cm,结节数量≤5,甲胎蛋白值≤500ng/ml),作为新的规定,5 年复发率的 95%置信区间为 7.3%(5.2-9.3),合格患者人数增加 19%。此外,5-5-500 规则可以识别出米兰标准内和标准外的复发高风险患者。总之,新的标准-5-5-500 规则可能为 HCC 的 LDLT 候选者提供合理的扩展。

相似文献

1
Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study.基于日本全国性调查的扩大活体供肝肝移植标准用于肝细胞癌患者:5-5-500 规则-一项回顾性研究。
Transpl Int. 2019 Apr;32(4):356-368. doi: 10.1111/tri.13391. Epub 2019 Jan 18.
2
Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.第 5 节:进一步扩大活体肝移植中 HCC 的标准:何时不移植:SNUH 经验。
Transplantation. 2014 Apr 27;97 Suppl 8:S20-3. doi: 10.1097/01.tp.0000446269.20934.d3.
3
Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.影响活体肝移植后肝细胞癌复发患者生存的预后因素:特别关注中性粒细胞/淋巴细胞比值。
Transplantation. 2013 Dec 15;96(11):1008-12. doi: 10.1097/TP.0b013e3182a53f2b.
4
Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).米兰标准(巴塞罗那临床肝癌扩展标准)以外肝癌患者的亲体肝移植的初步研究。
Liver Transpl. 2018 Mar;24(3):369-379. doi: 10.1002/lt.24977.
5
Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.去γ-羧基凝血酶原在活体肝移植治疗复发性肝细胞癌中的预后影响
Transplant Proc. 2015 Apr;47(3):703-4. doi: 10.1016/j.transproceed.2014.09.178. Epub 2015 Mar 27.
6
Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.活体肝移植前局部区域治疗对韩国肝细胞癌患者总生存期和无复发生存期的影响。
HPB (Oxford). 2016 Jan;18(1):98-106. doi: 10.1016/j.hpb.2015.08.008. Epub 2015 Dec 9.
7
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series.活体供肝肝移植治疗肝细胞癌:东京大学系列研究
Dig Dis. 2007;25(4):310-2. doi: 10.1159/000106910.
8
Living donor liver transplantation for hepatocellular carcinoma.肝细胞癌的活体供肝肝移植
Transplant Proc. 2012 Jul-Aug;44(6):1713-6. doi: 10.1016/j.transproceed.2012.05.033.
9
A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.一种利用血清甲胎蛋白水平的修订评分系统,以扩大肝细胞癌活体供体移植的候选者范围。
Surgery. 2007 May;141(5):598-609. doi: 10.1016/j.surg.2006.11.006. Epub 2007 Mar 23.
10
Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.甲胎蛋白对肝细胞癌活体肝移植受者生存的预测价值
Hepatogastroenterology. 2014 May;61(131):747-51.

引用本文的文献

1
Modern approach to hepatocellular carcinoma treatment.肝细胞癌治疗的现代方法。
World J Hepatol. 2025 Aug 27;17(8):107873. doi: 10.4254/wjh.v17.i8.107873.
2
Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.在日本基于终末期肝病模型评分的分配政策下,成人慢性终末期肝病候选者接受已故供体肝移植的等待名单死亡率及移植概率的现状。
J Gastroenterol. 2025 Aug 14. doi: 10.1007/s00535-025-02288-y.
3
Review Article: Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.
综述文章:免疫检查点抑制剂时代肝细胞癌的肝移植治疗
Aliment Pharmacol Ther. 2025 Sep;62(6):585-601. doi: 10.1111/apt.70333. Epub 2025 Aug 13.
4
Liver transplantation for HCC within and beyond Milan Criteria: single center experience with literature review.米兰标准内外肝细胞癌的肝移植:单中心经验及文献综述
Front Surg. 2025 Jul 10;12:1594361. doi: 10.3389/fsurg.2025.1594361. eCollection 2025.
5
Recent Strategies to Attenuate Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Narrative Review.肝移植后减轻肝细胞癌复发的近期策略:一项叙述性综述
Cancers (Basel). 2025 May 13;17(10):1650. doi: 10.3390/cancers17101650.
6
Liver transplantation as a treatment for cancer: comprehensive review.肝移植作为癌症的一种治疗方法:综述
BJS Open. 2025 May 7;9(3). doi: 10.1093/bjsopen/zraf034.
7
Development and Validation of a Pre-Transplant Risk Score (LT-MVI Score) to Predict Microvascular Invasion in Hepatocellular Carcinoma Candidates for Liver Transplantation.用于预测肝移植候选肝细胞癌患者微血管侵犯的移植前风险评分(LT-MVI评分)的开发与验证
Cancers (Basel). 2025 Apr 24;17(9):1418. doi: 10.3390/cancers17091418.
8
Evolving Transplant Oncology: Evolving Criteria for Better Decision-Making.不断发展的移植肿瘤学:用于更好决策的不断演变的标准。
Diagnostics (Basel). 2025 Mar 24;15(7):820. doi: 10.3390/diagnostics15070820.
9
Evolving Indications for Liver Transplantation for Hepatocellular Carcinoma Following the Milan Criteria.米兰标准之后肝细胞癌肝移植的不断变化的适应证
Cancers (Basel). 2025 Feb 3;17(3):507. doi: 10.3390/cancers17030507.
10
Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies.多学科策略时代的肝细胞癌外科治疗
Int J Clin Oncol. 2025 Mar;30(3):417-426. doi: 10.1007/s10147-025-02703-7. Epub 2025 Feb 5.